Monica Mark Discusses Patent Strategy Following Amgen vs Sanofi Patent Dispute

Reinhart shareholder Monica Mark was quoted in Nature Biotechnology, a leading, peer-reviewed scientific journal. In the article, which covers the Supreme Court of the United States decision in Amgen, Inc. v. Sanofi, Monica highlights a potential shift in patent strategy relating to invalidity challenges.

Monica is member of Reinhart’s Litigation and Intellectual Property practices, focusing on intellectual property disputes and appellate matters while helping clients successfully navigate volatile or complex legal proceedings. Advising on patent cases from the filing of the complaint through claim construction, summary judgment and trial, she has substantial experience in trademark, trade dress and copyright litigation.

Monica recently authored a detailed client alert examining the Amgen case and the enablement requirement of the Patent Act.